EUROFINS TRANSPLANT GENOMICS, LLC

Eurofins Transplant Genomics, LLC specializes in advanced genomic analysis services for transplant compatibility and immunogenetic profiling. Their core capabilities center on high-throughput HLA typing, donor-recipient matching algorithms, and molecular diagnostics for solid organ and hematopoietic stem cell transplantation. Leveraging next-generation sequencing platforms and bioinformatics pipelines, the company delivers precise, high-resolution genetic characterization critical to reducing graft rejection and improving transplant outcomes. Technical expertise includes SNP genotyping, allele-level HLA typing, and integration of immunogenomic data into clinical decision-support systems. Their differentiation lies in the rigorous quality control and regulatory alignment required for transplant laboratories serving federal and clinical research environments. No agency relationships can be inferred from available award data, as no contracting agencies or recent awards are documented in the provided history. Consequently, there is no demonstrable pattern of engagement with federal departments or health-related procurement entities. The primary NAICS code 621511—Medical and Diagnostic Laboratories—indicates a focus on clinical laboratory services involving genetic and molecular testing. In practice, this means the company operates as a specialized diagnostic provider within the transplant ecosystem, supporting clinical laboratories, transplant centers, and potentially research institutions requiring accredited genomic testing. Their market positioning is niche, serving the highly regulated transplant medicine sector with precision genomics solutions. Eurofins Transplant Genomics, LLC is structured as a single-entity business headquartered in Lenexa, Kansas. The company holds no government certifications, and its geographic footprint appears limited to its operational base. Without documented federal contracts, its government market presence cannot be confirmed, though its technical services align with capabilities required by agencies overseeing transplant programs and biomedical research.